Royal Bank Of Canada Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $708.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price objective lifted by investment analysts at Royal Bank Of Canada from $704.00 to $708.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “sector perform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of 8.25% from the company’s current price.

Several other equities research analysts have also weighed in on REGN. Morgan Stanley dropped their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, October 23rd. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Bank of America increased their target price on Regeneron Pharmaceuticals from $543.00 to $627.00 and gave the stock an “underperform” rating in a research report on Wednesday. Finally, Citigroup increased their target price on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $813.78.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $654.04 on Wednesday. Regeneron Pharmaceuticals has a 12-month low of $476.49 and a 12-month high of $883.15. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock’s 50 day simple moving average is $580.56 and its 200 day simple moving average is $564.66. The firm has a market cap of $69.32 billion, a P/E ratio of 15.66, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. During the same period last year, the company earned $12.46 earnings per share. The firm’s revenue for the quarter was up .9% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of REGN. Activest Wealth Management boosted its stake in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Saudi Central Bank bought a new position in Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $31,000. Institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.